IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

Core Insights - IDEAYA Biosciences has appointed Dr. Theodora (Theo) Ross as Chief Development Officer to lead early clinical development and guide long-term R&D strategy [1] - Dr. Ross has over 30 years of oncology experience, previously serving as Vice President at AbbVie, where she advanced five early clinical stage programs and was involved in a $10 billion acquisition [1] - The company focuses on precision medicine and aims to develop transformative therapies for cancer, with a pipeline centered on synthetic lethality and antibody-drug conjugates [1] Company Overview - IDEAYA Biosciences is a precision medicine oncology company dedicated to discovering, developing, and commercializing targeted therapies for cancer [1] - The company integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics to develop tailored therapies aligned with genetic disease drivers [1] - IDEAYA's mission is to create selective, effective, and personalized oncology therapies to improve clinical outcomes for cancer patients [1] Leadership Appointment - Dr. Ross's role will be crucial in advancing IDEAYA's clinical development plans and supporting the company's growth [1] - She expressed excitement about joining IDEAYA and emphasized the importance of scientific rigor and focus in oncology [1] - Dr. Ross's background includes leadership roles in global pharma companies and significant academic experience in cancer genetics [1]